Plain-English translation of NCT06182969 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is an early-stage trial testing a new medication called for people with mild-to-moderate lupus. About 40 participants will receive either the medication at various doses or a placebo (a dummy pill with no active ingredient). The study will look at how safe the medication is, how your body processes it, and whether it helps improve lupus symptoms.
Lupus is a serious autoimmune condition that can be hard to control. Researchers are studying this medication to see if it could offer a new treatment option for people whose lupus isn't severe but still causes troubling symptoms.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to either take the new medication at increasing doses (starting at 200mg and going up to 800mg) or a placebo. You won't know which one you're receiving—that's the 'double-blind' part, which helps make the results fair. You'll visit the clinic for check-ups and blood tests so doctors can watch for any side effects and see how the medication is working in your body.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
China
Sponsor
Ascentage Pharma Group Inc.
Collaborators
Suzhou Yasheng Pharmaceutical Co., Ltd.
Enrollment target
~40 participants
Started
August 2024
Primary completion
April 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Sex
Female only
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yifan Zhai
Renji Hospital Shanghai Jiaotong University School of Medical
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.